Catheter Precision enters agreement to divest atherectomy catheter technologies

Catheter Precision (VTAK) announced it has entered into a definitive agreement to divest its atherectomy catheter technologies, including associated FDA approvals and patents, to a strategic acquirer. Following a comprehensive portfolio review, the Company determined that monetizing these non-core assets enhances capital efficiency and sharpens focus on its high-growth electrophysiology platform. Transaction Highlights: Upfront cash payment following closing of $15,000; A 5% equity stake in the acquiring company with anti-dilution protection up to $5 million of additional equity capital being invested in the acquiring company; Ten-year royalty payments agreement on net sales: 1.5% baseline and Increases to 3% on quarterly net sales above $5 million.